4 research outputs found
Hydrogel Nanostructures for Targeted Drug Delivery in Inflammatory Diseases: A Comprehensive Review
No full textIn the treatment of inflammatory illnesses, hydrogel nanostructures have shown themselves to be a flexible and promising substrate for targeted drug delivery. The biocompatibility, biodegradability, and controlled, localised drug release capabilities of these systems are highly regarded because they minimise systemic adverse effects and improve therapeutic efficacy. Systems based on hydrogel may be made to react to environmental cues like pH, temperature, or enzymatic activity that are frequently present in inflammatory tissues. Treatment results are improved by this responsiveness, which enables precise medication release at the location of inflammation. Targeting ligands, including peptides or antibodies, are added to improve the efficiency and specificity of medication delivery. By selectively binding to markers produced in inflammatory tissues, these ligands allow hydrogel nanostructures to improve medication accumulation at the intended region while minimising off-target effects. These developments might have a significant impact on diseases including psoriasis, inflammatory bowel illness, and rheumatoid arthritis. Clinical translation is nevertheless hampered by issues including stability, consistent biocompatibility, and manufacturing scalability, despite their potential. These restrictions should be solved by upcoming developments including combination medicines, stimuli-responsive hydrogels, and personalised medicine strategies. By providing more accurate control over medication distribution, these tactics may allow for patient-specific therapies and enhance overall results. A potential strategy for creating patient-centered, long-lasting, and efficient treatments for chronic inflammatory illnesses is the use of hydrogel nanostructures. These systems have the potential to revolutionise the treatment of a variety of inflammatory diseases by tackling present issues and utilising creative design techniques
Nanotechnology for Diabetes Management: Transforming Anti-diabetic Drug Delivery Systems
No full textTo prevent major complications, people with chronic diabetes mellitus, a metabolic condition characterised by increased blood sugar, require continuous care. Although current pharmacological treatments, such as insulin and oral hypoglycemic agents, are effective, they are often limited by poor bioavailability, short half-life, and systemic side effects. Drug delivery systems based on nanotechnology provide encouraging answers to these problems, allowing for the targeted, precise, and regulated administration of anti-diabetic medications. In order to improve therapeutic efficacy, decrease the frequency of administration, and increase drug bioavailability, nanoparticles, liposomes, nanogels, and microneedles are becoming important technologies. For example, liposomes increase the solubility and durability of hydrophobic medications, whereas nanoparticles can shield medications from deterioration and enable continuous release. In response to hyperglycemia, nanogels that are engineered to react to particular stimuli, such as pH or glucose levels, allow regulated medication release that mimics the body\u27s normal production of insulin. Insulin and other anti-diabetic medications can be delivered painlessly via microneedles, a minimally invasive substitute for conventional injections. Notwithstanding these developments, issues with scalability, cost, regulatory approval, and long-term safety still affect the clinical translation of these technologies. This study looks at the state of diabetic medication delivery systems based on nanotechnology, emphasising how they have the potential to transform treatment approaches and enhance patient outcomes. Future research should focus on overcoming these barriers, conducting clinical trials, and exploring new nanomaterials to maximize the therapeutic potential of these systems
Navigating the Complexities of Alopecia Areata: A Comprehensive Analysis
No full textOne prevalent type of body and head hair loss that doesn\u27t leave scars is called alopecia areata (AA). In this Review, we studied the Pathogenesis of Alopecia Areata, Epidemiology, Cells implicated in alopecia areata immune reactions, Immunology, Environmental Factors, Genetic Factors, Causes of alopecia areata, Traditional Treatments of alopecia areata. The peer-reviewed literature release from 2010 & 2022 was thoroughly searched using Medline, Embase, Amed, Co-chrane Central Register of Controlled Trials, Psych INFO & Lilacs. All randomized controlled studies (RCTs) thatassessed efficacy systemic therapies for people with alopecia areata, totalis & universalis were included
Emerging Strategies for Targeted Drug Delivery across the Blood–Brain Barrier in Neurological Disorder
No full textThe Blood–Brain Barrier is an obstacle in the treatment of neurological disorders since it selectively only allows some substances to pass through. Its poor permeability greatly limits access of certain therapeutic agents in the brain. In order to successfully treat glioblastoma, Parkinson\u27s disease, Alzheimer\u27s disease, and other illnesses of the central nervous system, it will be crucial to overcome the Blood Brain Barrier. Recent developments in targeted drug delivery systems have presented promising potential for this challenge. Emerging strategies include nanotechnology-based systems, receptor-mediated transport, cell-penetrating peptides, focused ultrasound, and advanced carrier designs. Nanotechnology-based systems, including liposomes, polymeric nanoparticles, and SLNs, offer controlled drug release and improved bioavailability, while surface modifications enhance Blood–Brain Barrier penetration through receptor-specific targeting. By conjugating medications to ligands that attach to certain receptors on Blood–Brain Barrier endothelial cells, receptor-mediated transport strategies facilitate active transport across the barrier. Cell-penetrating peptides are short peptides that have been utilised to deliver a variety of medicinal substances because they can pass through cell membranes. When combined with microbubbles, focused ultrasounds can momentarily breach the Blood Brain Barrier, enabling tailored medication administration without the need for invasive procedures. In addition, sophisticated carrier designs like dendrimers and mesoporous silica nanoparticles enhance drug stability and provide prolonged release. These strategies have great promise in improving drug delivery into the brain, treatment efficacy, and minimizing side effects
